Argos garners $35.2M in third round

TVM Capital led a hefty $35.2 million third round of venture capital for Colorado's Argos Therapeutics. The funding will be used to support Argos' Phase II trial of Arcelis immunotherapy drug candidates in renal cell carcinoma and HIV. In addition, it will finance the company's CD83 protein immunology program through an initial human clinical trial in transplantation.

"We believe that the Company's many near-term data events, combined with its ability to move into additional cancer and infectious disease indications with its Arcelis platform technology, as well autoimmune disorders with its CD83 soluble protein, position Argos as a leader in the immunotherapy field," said Hubert Birner, Ph.D., General Partner of TVM Capital and Argos' Chairman. Argos was featured in FierceBiotech's weekly column on emerging drug developers. 

- see this Argos release

Related Articles:
Argos, J&J make a deal
Argos, Therakos ink deal
In VC market, life sciences dominate

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.